Reporting owner · CIK 0002114309
Xu Cong Claire
Visual SEC Form 4 history across 1 companies, 3 transactions and 1 filings.
EVP, CDEVP, Clinical DevelopmentNovaBridge Biosciences
Open-market mix
0%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Aug 26
−$2.6K
Transaction texture
Ownership and ticket size
Average P/S size$2.6K
Median P/S size$2.6K
Direct3
Indirect0
Aug 31, 2026sale
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest buy
No open-market insider purchase is available.
Associated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| NBP | Xu Cong Claire | EVPCD | exercise | 4.07k | $0 | M | — | 09/01 | 08/30 | |
| NBP | Xu Cong Claire | EVPCD | sale | 3.28k | -$259k | S | — | 09/01 | 08/31 | |
| NBP | Xu Cong Claire | EVPCD | exercise | 9.38k | — | M | — | 09/01 | 08/30 |
Xu Cong Claire Insider Activity FAQ
SEC Form 4 context
Who is Xu Cong Claire?
Xu Cong Claire is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002114309.
Which companies has Xu Cong Claire reported transactions for?
NovaBridge Biosciences
When was Xu Cong Claire's latest insider buy?
No open-market insider purchase is available for this period.
When was Xu Cong Claire's latest insider sale?
sale at NovaBridge Biosciences on Aug 31, 2026 valued at $2,593.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.